The potential role of nanobodies in asthma therapy
Asthma is a chronic inflammatory disease of the airways characterized by bronchoconstriction, airway hyperresponsiveness, and mucus production. The pathophysiology of asthma involves a complex interplay of immune cells and mediators, including cytokines, chemokines, and other inflammatory molecules....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1510806/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832593944433655808 |
|---|---|
| author | Baraa Khalid Salah Al-Sheakly Fatemeh Saheb Sharif-Askari Fatemeh Saheb Sharif-Askari Narjes Saheb Sharif-Askari Narjes Saheb Sharif-Askari Jennifer E. Hundt Rabih Halwani Rabih Halwani |
| author_facet | Baraa Khalid Salah Al-Sheakly Fatemeh Saheb Sharif-Askari Fatemeh Saheb Sharif-Askari Narjes Saheb Sharif-Askari Narjes Saheb Sharif-Askari Jennifer E. Hundt Rabih Halwani Rabih Halwani |
| author_sort | Baraa Khalid Salah Al-Sheakly |
| collection | DOAJ |
| description | Asthma is a chronic inflammatory disease of the airways characterized by bronchoconstriction, airway hyperresponsiveness, and mucus production. The pathophysiology of asthma involves a complex interplay of immune cells and mediators, including cytokines, chemokines, and other inflammatory molecules. Despite advances in asthma management, many patients continue to experience symptoms due to the limitations of current therapies. Monoclonal antibodies (mAbs) targeting specific inflammatory mediators have improved treatment outcomes for some patients, but challenges such as poor tissue penetration and high costs remain. Nanobodies (Nbs), a novel class of single-domain antibodies, offer a promising alternative due to their small size, stability, and potential for enhanced tissue penetration. This review discusses the key mediators involved in asthma, challenges in current treatments, and the potential of Nbs as a new therapeutic strategy. We also explore current studies and innovations in nanobody technology. |
| format | Article |
| id | doaj-art-9182042aedb24b7981f9e0666f9d575c |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-9182042aedb24b7981f9e0666f9d575c2025-01-20T07:20:15ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15108061510806The potential role of nanobodies in asthma therapyBaraa Khalid Salah Al-Sheakly0Fatemeh Saheb Sharif-Askari1Fatemeh Saheb Sharif-Askari2Narjes Saheb Sharif-Askari3Narjes Saheb Sharif-Askari4Jennifer E. Hundt5Rabih Halwani6Rabih Halwani7Research Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Pharmacy Practice and Pharmacotherapeutics, College of Pharmacy, University of Sharjah, Sharjah, United Arab EmiratesResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Clinical Sciences, College of Medicine, University of Sharjah, Sharjah, United Arab EmiratesLübeck Institute of Experimental Dermatology, University of Lübeck, Lübeck, GermanyResearch Institute for Medical and Health Sciences, University of Sharjah, Sharjah, United Arab EmiratesDepartment of Pediatrics, Faculty of Medicine, Prince Abdullah Ben Khaled Celiac Disease Chair, King Saud University, Riyadh, Saudi ArabiaAsthma is a chronic inflammatory disease of the airways characterized by bronchoconstriction, airway hyperresponsiveness, and mucus production. The pathophysiology of asthma involves a complex interplay of immune cells and mediators, including cytokines, chemokines, and other inflammatory molecules. Despite advances in asthma management, many patients continue to experience symptoms due to the limitations of current therapies. Monoclonal antibodies (mAbs) targeting specific inflammatory mediators have improved treatment outcomes for some patients, but challenges such as poor tissue penetration and high costs remain. Nanobodies (Nbs), a novel class of single-domain antibodies, offer a promising alternative due to their small size, stability, and potential for enhanced tissue penetration. This review discusses the key mediators involved in asthma, challenges in current treatments, and the potential of Nbs as a new therapeutic strategy. We also explore current studies and innovations in nanobody technology.https://www.frontiersin.org/articles/10.3389/fphar.2024.1510806/fullasthmacytokineinflammatory mediatorsmonoclonal antibodiesnanobodies (Nbs) |
| spellingShingle | Baraa Khalid Salah Al-Sheakly Fatemeh Saheb Sharif-Askari Fatemeh Saheb Sharif-Askari Narjes Saheb Sharif-Askari Narjes Saheb Sharif-Askari Jennifer E. Hundt Rabih Halwani Rabih Halwani The potential role of nanobodies in asthma therapy Frontiers in Pharmacology asthma cytokine inflammatory mediators monoclonal antibodies nanobodies (Nbs) |
| title | The potential role of nanobodies in asthma therapy |
| title_full | The potential role of nanobodies in asthma therapy |
| title_fullStr | The potential role of nanobodies in asthma therapy |
| title_full_unstemmed | The potential role of nanobodies in asthma therapy |
| title_short | The potential role of nanobodies in asthma therapy |
| title_sort | potential role of nanobodies in asthma therapy |
| topic | asthma cytokine inflammatory mediators monoclonal antibodies nanobodies (Nbs) |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1510806/full |
| work_keys_str_mv | AT baraakhalidsalahalsheakly thepotentialroleofnanobodiesinasthmatherapy AT fatemehsahebsharifaskari thepotentialroleofnanobodiesinasthmatherapy AT fatemehsahebsharifaskari thepotentialroleofnanobodiesinasthmatherapy AT narjessahebsharifaskari thepotentialroleofnanobodiesinasthmatherapy AT narjessahebsharifaskari thepotentialroleofnanobodiesinasthmatherapy AT jenniferehundt thepotentialroleofnanobodiesinasthmatherapy AT rabihhalwani thepotentialroleofnanobodiesinasthmatherapy AT rabihhalwani thepotentialroleofnanobodiesinasthmatherapy AT baraakhalidsalahalsheakly potentialroleofnanobodiesinasthmatherapy AT fatemehsahebsharifaskari potentialroleofnanobodiesinasthmatherapy AT fatemehsahebsharifaskari potentialroleofnanobodiesinasthmatherapy AT narjessahebsharifaskari potentialroleofnanobodiesinasthmatherapy AT narjessahebsharifaskari potentialroleofnanobodiesinasthmatherapy AT jenniferehundt potentialroleofnanobodiesinasthmatherapy AT rabihhalwani potentialroleofnanobodiesinasthmatherapy AT rabihhalwani potentialroleofnanobodiesinasthmatherapy |